Molecular docking studies were performed to evaluate the binding affinity and interaction profiles of ten bioactive compounds from BRLE against the four key protein targets (EGFR, SRC, STAT3, and AKT1) identified through network pharmacology analysis for ulcerative colitis treatment. This evidence concerns the gene AKT1 and ulcerative colitis.